Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

AccesswireDec 20 05:05

Clear Street Launches Healthcare & Biotechnology Equity Research

BusinesswireDec 18 03:00

BTIG Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Maintains Target Price $67

Futu NewsDec 11 02:32 · Ratings

JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58

Futu NewsDec 11 01:32 · Ratings

Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda Partnership

TipRanksDec 11 01:05 · Ratings

H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $50

Futu NewsDec 10 20:31 · Ratings